Trials / Terminated
TerminatedNCT04230954
Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
A Phase II Study of Cabozantinib (XL184) Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- University of South Alabama · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Drug: Cabozantinib Drug: Pembrolizumab
Detailed description
This study is a multi-center, single arm, open label trial to evaluate the efficacy and safety of Cabozantinib (XL184) plus Pembrolizumab in recurrent, persistent and/or metastatic cervical cancer with PD-L1 tumor positivity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cabozantinib 40 MG oral once a day | Cabozantinib 40 mg oral once a day |
| DRUG | Pembrolizumab 200 mg IV every 3 weeks | Pembrolizumab 200 mg IV every 3 weeks |
Timeline
- Start date
- 2020-04-16
- Primary completion
- 2022-02-16
- Completion
- 2022-02-16
- First posted
- 2020-01-18
- Last updated
- 2022-06-07
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04230954. Inclusion in this directory is not an endorsement.